Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Breast Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Melanoma 5COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Cholangiocarcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Hydroxychloroquine × Clear all
NCT01506973 2025-07-25

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
119 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01206530 2019-04-18

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
50 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡